InvestorsHub Logo
Followers 7
Posts 289
Boards Moderated 0
Alias Born 12/11/2013

Re: georgejjl post# 163232

Sunday, 11/06/2016 9:43:09 AM

Sunday, November 06, 2016 9:43:09 AM

Post# of 403025
Sounds like Taltz has some nasty side effects:

For Healthcare Professionals
Applies to ixekizumab: subcutaneous solution

Dermatologic
Common (1% to 10%): Urticaria
Uncommon (0.1% to 1%): Angioedema[Ref]

Gastrointestinal
Common (1% to 10%): Nausea
Uncommon (0.1% to 1%): Oral candidiasis, inflammatory bowel disease[Ref]

Hematologic
Very common (10% or more): Neutropenia (11%)
Common (1% to 10%): Thrombocytopenia[Ref]

Immunologic
Very common (10% or more): Infections (26%), immunogenicity (22%)
Common (1% to 10%): Tinea infections, influenza
Uncommon (0.1% to 1%): Serious infections[Ref]

Local
Very common (10% or more): Injection site reactions (17%), erythema, pain[Ref]

Ocular
Common (1% to 10%): Conjunctivitis[Ref]

Respiratory
Very common (10% or more): Upper respiratory tract infections (including nasopharyngitis and rhinovirus infection) (14%)
Uncommon (0.1% to 1%): Rhinitis[Ref]

References
1. "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company, Indianapolis, IN.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News